OppenheimerFunds’s Emergent Biosolutions EBS Stock Holding History

OppenheimerFunds’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$19.4M	Buy	383,787 +10,804	+3%	+$637K	0.02%	547
2018 Q4	$22.1M	Buy	372,983 +18,423	+5%	+$1.19M	0.03%	475
2018 Q3	$23.3M	Buy	354,560 +12,970	+4%	+$757K	0.03%	548
2018 Q2	$17.2M	Buy	341,590 +8,507	+3%	+$443K	0.02%	613
2018 Q1	$17.5M	Buy	333,083 +1,325	+0.4%	+$66K	0.02%	597
2017 Q4	$15.4M	Buy	331,758 +321,918	+3,272%	+$13.6M	0.02%	662
2017 Q3	$398K	Sell	9,840 -2,631	-21%	-$95.2K	﹤0.01%	1610
2017 Q2	$422K	Sell	12,471 -87	-0.7%	-$2.69K	﹤0.01%	1583
2017 Q1	$364K	Buy	12,558 +2,351	+23%	+$71.6K	﹤0.01%	1633
2016 Q4	$335K	Buy	10,207 +923	+10%	+$27.7K	﹤0.01%	1561
2016 Q3	$293K	Buy	+9,284	New	+$270K	﹤0.01%	1502
2016 Q2	–	Sell	-6,706	Closed	-$244K	–	1709
2016 Q1	$244K	Sell	6,706 -1,013	-13%	-$35.8K	﹤0.01%	1529
2015 Q4	$309K	Buy	+7,719	New	+$269K	﹤0.01%	1500

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds's EBS Position: Q1 2019 in Review

OppenheimerFunds increased its Emergent Biosolutions (EBS) stake by 2.9% in Q1 2019, buying an estimated $637K and bringing the position to 383,787 shares worth $19.4M. The position accounts for 0.02% of the portfolio, ranked #547.

OppenheimerFunds first reported a position in EBS in Q4 2015 and has held it in 13 quarters since. The position peaked at $23.3M in Q3 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

OppenheimerFunds held 383,787 shares of Emergent Biosolutions worth $19.4M as of Q1 2019.
OppenheimerFunds bought 10,804 Emergent Biosolutions shares in Q1 2019, an estimated $637K.
Emergent Biosolutions made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #547 holding.
OppenheimerFunds first reported a position in Emergent Biosolutions in Q4 2015 and has held it in 13 quarters since.
OppenheimerFunds's Emergent Biosolutions position peaked at $23.3M in Q3 2018.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.